Juno Therapeutics, Inc. clinical trials

Acquired by Bristol-Myers Squibb, Nov 20, 2019 · source ↗

The registry lists 29 studies whose lead sponsor is Juno Therapeutics, Inc.. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 6, 2026.

Studies

Recruiting first, then most recently updated. Showing 29 of 29. All Bristol-Myers Squibb studies →

• Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06297226Phase 2

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingNCT07015242Phase 2

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)Not yet recruitingNCT07848295Phase 1

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingNCT07335562Phase 3

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingNCT06615479Phase 3

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06121843Phase 1

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRecruitingNCT07115745Phase 1

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)Not yet recruitingNCT07603557Phase 2

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06153251Phase 1

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• Nonconforming Lisocabtagene Maraleucel Expanded Access ProtocolAvailableNCT04400591

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted after Juno Therapeutics became part of Bristol-Myers Squibb

• A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788639

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingRecruitingNCT06794268

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788652

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Active, not recruitingNCT06220201Phase 1

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)Active, not recruitingNCT05869955Phase 1

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)Active, not recruitingNCT07015983Phase 2

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03331198Phase 1/2

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaWithdrawnNCT06313996Phase 3

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04674813Phase 1

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted after Juno Therapeutics became part of Bristol-Myers Squibb

• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 2

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT04394650Phase 1

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted after Juno Therapeutics became part of Bristol-Myers Squibb

• Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03430011Phase 1/2

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT04231747Phase 1

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted after Juno Therapeutics became part of Bristol-Myers Squibb

• A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnNCT06205290Phase 3

  Sponsor listed in the registry: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb

• Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)CompletedNCT03483103Phase 2

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• Long-Term Follow-up Study for Patients Previously Treated With JCAR015CompletedNCT02813252

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT02535364Phase 2

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb

• Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771

  Sponsor listed in the registry: Juno Therapeutics, a Subsidiary of Celgene · First submitted before Juno Therapeutics became part of Bristol-Myers Squibb